Ultima-Semaglutide 5mg

Manufacturer: Ultima Pharmaceuticals

Pharmaceutical name: Semaglutide

Pack: 1 vial (5 mg)

Semaglutide is an effective once-weekly GLP-1 receptor agonist that significantly lowers HbA1c, reduces body weight, and decreases systolic blood pressure. However, it is linked to a higher occurrence of gastrointestinal side effects. Further evaluation of its implications concerning pancreatitis and retinopathy is necessary through post-approval pharmacovigilance studies.

 

Highlights:

-Semaglutide studies as an appetite suppressant and for weight loss.

-Semaglutide in prediabetes 

 

Once-Weekly Semaglutide in Adults with Overweight or Obesity

 

A phase 3, double-blind, randomized, controlled trial was conducted to compare semaglutide with a placebo, alongside lifestyle modifications, in overweight or obese adults without diabetes. A total of 1961 participants received either 2.4 mg of subcutaneous semaglutide (with a gradual increase to this dose) or a placebo each week for 68 weeks; both groups participated in a counseling program focused on diet and exercise. The co-primary endpoints were the percentage change in body weight and weight loss of ≥5%.

 

Results Efficacy: At week 68, the average weight loss was greater with semaglutide than with placebo (14.9% vs. 2.4%; estimated difference, −12.4 percentage points; 95% CI, −13.4 to −11.5). Furthermore, a higher percentage of participants in the semaglutide group achieved weight loss of ≥5% compared to the placebo group (86.4% vs. 31.5%). Safety: Most adverse events, primarily gastrointestinal, were mild to moderate in severity, although treatment was discontinued by 7.0% of those in the semaglutide group and 3.1% of the placebo group. Serious adverse events, particularly gastrointestinal and hepatobiliary issues, were reported more frequently in the semaglutide group.

 

Conclusions: Overweight or obese adults without diabetes experienced clinically significant weight loss with weekly semaglutide injections (2.4 mg) combined with lifestyle modifications.

 

Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis

 

A total of 6 placebo-controlled and 7 active-controlled studies involving subcutaneous semaglutide were included. We found only one trial that involved oral semaglutide. In comparison to placebo, subcutaneous semaglutide at doses of 0.5 and 1 mg reduced HbA1c by 1.01% (95% CI, 0.56-1.47) and 1.38% (1.05-1.70), respectively. Both doses showed superior glycemic effectiveness compared to other antidiabetic medications, including sitagliptin, exenatide, liraglutide, dulaglutide, and insulin glargine.

 

Semaglutide also had a positive impact on body weight (mean difference vs. placebo −4.11 kg, 95% CI −4.85 to −3.37 for semaglutide 1 mg) and systolic blood pressure. No increased rates of hypoglycemia were observed with semaglutide; however, there was a noted rise in the incidence of nausea, vomiting, and diarrhea. Instances of pancreatitis were rare, and the odds ratio for diabetic retinopathy compared to placebo was 1.32 (95% CI, 0.98-1.77).